Artemis Pharmaceuticals and Cibasa Collaborate on Cancer Therapies

Strategic Insights -

Artemis Pharmaceuticals GmbH and the Spanish biotechnology company Center for Applied Molecular Research Salamanca (Cibasa) have announced a worldwide marketing agreement to collaborate on marketing Cibasa's Oncostem technology. This technology is based on cancer stem cell (CSC) research and will be used to discover and develop novel anticancer therapies. Cibasa's Oncostem technology includes a collection of mouse models that mimic human cancers and respond to therapeutic agents similar to those observed in patients. Artemis, a leader in generating genetically modified mouse models, will utilize its marketing network and technology to offer research collaborations and scientific services to pharmaceutical and biotechnology companies.

Key Takeaways:

  • Artemis Pharmaceuticals GmbH and the Center for Applied Molecular Research Salamanca (Cibasa) have signed a worldwide marketing agreement to collaborate on marketing Cibasa's Oncostem technology.
  • Cibasa's Oncostem technology is based on cancer stem cell (CSC) research and includes a collection of novel cancer mouse models that mimic human cancers.
  • Artemis will utilize its marketing network and technology to offer research collaborations and scientific services to pharmaceutical and biotechnology companies.
  • The collaboration aims to develop highly innovative cancer therapies by targeting cancer stem cells.
  • Prof. Peter Stadler, Managing Director of Artemis, stated that the company is "extremely pleased" about the new relationship with Cibasa.
  • Prof. Juan Luis Gonzalez, Chairman of Cibasa, expressed that the marketing agreement will allow both companies to optimize their resources.

Statistics:

  • Cibasa has developed a revolutionary science platform based on targeting cancer stem cells.
  • Artemis has a large international network of customers from the pharmaceutical and biotechnology industries.
  • The collaboration includes opportunities for research collaborations, scientific services, and drug candidate testing.
  • The goal of the collaboration is to discover and develop novel anticancer therapies.
  • Artemis is the leading company for the generation of tailor-made genetically modified mouse models.

Sources:

  • Artemis Pharmaceuticals GmbH
  • Center for Applied Molecular Research Salamanca (Cibasa)
  • Health & Medicine Week
  • NewsRx.com